Source link : https://www.newshealth.biz/health-news/durvalumab-boosts-survival-in-muscle-invasive-bladder-cancer/
BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) significantly improved survival, reducing the risk for death by 25%, according to a preplanned interim analysis of the phase 3 NIAGARA trial. These results offer practice-changing evidence in an area of unmet need, said lead investigator Thomas Powles, MD, […]
Author : News Health
Publish date : 2024-09-17 13:10:37
Copyright for syndicated content belongs to the linked Source.